Cancer Care Ontario | Cancer Care Ontario

You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.

Skip to main content Skip to search

1944 Results

Guidelines and Advice

An Endorsement of the 2018 Guideline on Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline

Status: In-Review
ID: 3-22
Version: N/A

Apr 2020

Guidelines and Advice

An Endorsement of the 2021 Guideline on Chemotherapy in Combination with Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline

Status: Current
ID: GL END 5-7
Version: 3

Nov 2021

Updated Reference Population, Age-Standardized Rates

Guidelines and Advice

Plerixafor for Autologous Hematopoietic Stem Cell Mobilization and Transplantation for Patients in Ontario

Status: Current
ID: SCT-7

Sep 2015

Guidelines and Advice

The Role of IMRT in Head and Neck Cancer

Status: Archived
ID: 21-3-3

Jan 2011

Biosimilars – What You Need to Know – for Providers

Cancer facts

Les cancers de la peau en augmentation chez les adultes

May 2021

Guidelines and Advice

The Role of IMRT in Soft-Tissue Sarcomas

Status: Archived
ID: 21-3-6

Oct 2010

Guidelines and Advice

Cancer Screening for Persons at Risk for or Affected with Lynch Syndrome Evidence Summary

Status: In-Review
ID: ES 15-16

Oct 2018

Registered Nurse Flexible Sigmoidoscopy

Comprehensive Cancer Biomarker Testing Program - As of July 1, 2025

Our Comprehensive Cancer Biomarker Testing Program supports patient management through the testing of diagnostic, predictive and prognostic markers....

Guidelines and Advice

An Endorsement of the 2021 Cancer Care Alberta Clinical Practice Guideline on Uveal Melanoma

Status: Current
ID: C50-CIDAP-1

Mar 2024

Pages